Surgical management of disappearing colorectal liver metastases

British Journal of Surgery

Volumn 100, Issue 11, 2013, Pages 1414-1420

  Bischof, D A ^a   Clary, B M ^b   Maithel, S K ^c   Pawlik, T M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LIVER TUMOR; METASTASIS; METASTASIS RESECTION; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOPERATIVE PERIOD; REVIEW; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; METASTASECTOMY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PERIOPERATIVE CARE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84883487245     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9213     Document Type: Review

References (43)

1. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-308.
2. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
3. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
4. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
7. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
8. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
9. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
10. Fuchs CS, Marshall J, Barrueco J,. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-690.
11. Blazer DG III, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
12. Adam R, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26: 1635-1641.
13. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657.
14. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939-3945.
15. Elias D, Goere D, Boige V, Kohneh-Sharhi N, Malka D, Tomasic G, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194.
16. Elias D, Youssef O, Sideris L, Dromain C, Baton O, Boige V, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004; 86: 4-9.
17. Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502-1509.
18. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA,. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 2010; 14: 1691-1700.
19. Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I,. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 2009; 250: 935-942.
20. Gaujoux S, Goéré D, Dumont F, Souadka A, Dromain C, Ducreux M, et al. Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect? Dig Surg 2011; 28: 114-120.
21. Zalinski S, Abdalla EK, Mahvash A, Vauthey JN,. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 2009; 16: 1208-1211.
22. Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF, Davidson BR,. Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 2004; 91: 1361-1369.
23. Kamel IR, Choti MA, Horton KM, Braga HJ, Birnbaum BA, Fishman EK, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology 2003; 227: 752-757.
24. Kuszyk BS, Bluemke DA, Urban BA, Choti MA, Hruban RH, Sitzmann JV, et al. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings. AJR Am J Roentgenol 1996; 166: 91-95.
25. Kondo H, Kanematsu M, Hoshi H, Murakami T, Kim T, Hori M, et al. Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT. AJR Am J Roentgenol 2000; 174: 947-954.
26. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK,. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274-286.
27. Oliva MR, Mortele KJ, Segatto E, Glickman JN, Erturk SM, Ros PR, et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 2006; 30: 37-43.
28. Albrecht T, Blomley MJ, Burns PN, Wilson S, Harvey CJ, Leen E, et al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study. Radiology 2003; 227: 361-370.
29. Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178: 282-287.
30. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM,. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11: 1112-1119.
31. Oudkerk M, van den Heuvel AG, Wielopolski PA, Schmitz PI, Borel Rinkes IH, Wiggers T,. Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology 1997; 203: 449-456.
32. van Etten B, van der Sijp J, Kruyt R, Oudkerk M, van der Holt B, Wiggers T,. Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases. Eur J Surg Oncol 2002; 28: 645-651.
33. Yamashita Y, Hatanaka Y, Yamamoto H, Arakawa A, Matsukawa T, Miyazaki T, et al. Differential diagnosis of focal liver lesions: role of spin-echo and contrast-enhanced dynamic MR imaging. Radiology 1994; 193: 59-65.
34. Peterson MS, Baron RL, Murakami T,. Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 1996; 201: 337-345.
35. Low RN, Francis IR, Herfkens RJ, Jeffrey RB Jr, Glazer GM, Foo TK, et al. Fast multiplanar spoiled gradient-recalled imaging of the liver: pulse sequence optimization and comparison with spin-echo MR imaging. AJR Am J Roentgenol 1993; 160: 501-509.
36. Larson RE, Semelka RC, Bagley AS, Molina PL, Brown ED, Lee JK,. Hypervascular malignant liver lesions: comparison of various MR imaging pulse sequences and dynamic CT. Radiology 1994; 192: 393-399.
37. Valls C, Iannacconne R, Alba E, Murakami T, Hori M, Passariello R, et al. Fat in the liver: diagnosis and characterization. Eur Radiol 2006; 16: 2292-2308.
38. van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM,. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 2012; 19: 2805-2813.
39. Smith JT, Ward J, Guthrie JA, Sheridan MB, Boyes S, Wilson D, et al. Detection of colorectal metastases in patients being treated with chemotherapy utilising SPIO-MRI: a radiological-pathological study. Magn Reson Imaging 2012; 30: 1446-1453.
40. Ferrero A, Langella S, Russolillo N, Vigano L, Lo Tesoriere R, Capussotti L,. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg 2012; 16: 806-814.
41. Ong KO, Leen E,. Radiological staging of colorectal liver metastases. Surg Oncol 2007; 16: 7-14.
42. Takahashi M, Hasegawa K, Arita J, Hata S, Aoki T, Sakamoto Y, et al. Contrast-enhanced intraoperative ultrasonography using perfluorobutane microbubbles for the enumeration of colorectal liver metastases. Br J Surg 2012; 99: 1271-1277.
43. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R,. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248: 626-637.